We will use your email address only for sending you newsletters. Please see our Privacy Notice for details of your data protection rights.
The new treatment, a monoclonal antibody therapy, aims to treat ‘mild to moderate’ COVID-19 cases, analysts said.
The treatment, called bamlanivimab, has been developed by Eli Lilly and Co. It was approved for use by the US Food and Drug Administration yesterday.
However, the drug cannot be used on patients who are hospitalised with the virus or who require oxygen therapy, or who are under 12 years of age.
The FDA said: “Through our Coronavirus Treatment Acceleration Program, the FDA continues to work around the clock and use every tool at our disposal toward these efforts.”
THIS IS A BREAKING STORY. MORE TO COME…
Source: Read Full Article